April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Efficacy of Besifloxacin in the Treatment of Methicillin-Resistant Staphylococcus aureus Keratitis
Author Affiliations & Notes
  • M. E. Marquart
    Microbiology, Univ of Mississippi Med Ctr, Jackson, Mississippi
  • M. E. Sanders
    Microbiology, Univ of Mississippi Med Ctr, Jackson, Mississippi
  • E. W. Norcross
    Microbiology, Univ of Mississippi Med Ctr, Jackson, Mississippi
  • Q. C. Moore, III
    Microbiology, Univ of Mississippi Med Ctr, Jackson, Mississippi
  • A. Shafiee
    Bausch & Lomb, Rochester, New York
  • Footnotes
    Commercial Relationships  M.E. Marquart, Bausch & Lomb, F; M.E. Sanders, Bausch & Lomb, F; E.W. Norcross, Bausch & Lomb, F; Q.C. Moore, III, Bausch & Lomb, F; A. Shafiee, Bausch & Lomb, E.
  • Footnotes
    Support  Bausch & Lomb
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2669. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. E. Marquart, M. E. Sanders, E. W. Norcross, Q. C. Moore, III, A. Shafiee; Efficacy of Besifloxacin in the Treatment of Methicillin-Resistant Staphylococcus aureus Keratitis. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2669.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the effectiveness of topically applied besifloxacin (0.6%), gatifloxacin (0.3%), and moxifloxacin (0.5%) for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis.

Methods: : One hundred colony-forming units (CFU) of MRSA (blood isolate, G.V. Sonny Montgomery V.A. Medical Center, Jackson, MS) were injected intrastromally into rabbit corneas. Ten hours after infection, one topical drop of PBS, besifloxacin, gatifloxacin, or moxifloxacin was applied to each eye every 15 minutes for 5 doses and then every 30 minutes for 14 doses. Eyes were examined before and after treatment by slit lamp biomicroscopy. Corneas were harvested from treated and untreated rabbits for the quantitation of bacteria. Minimal inhibitory concentrations (MICs) were determined in vitro for each fluoroquinolone.

Results: : The baseline log10 CFU recovered from corneas prior to treatment was 6.713 ± 0.093. Besifloxacin was most effective at reducing the bacterial CFU following treatment (P < 0.001 compared to the PBS group; n = 12 corneas per group). The average log10 CFU of MRSA recovered from besifloxacin-treated corneas (3.569 ± 0.378) was significantly lower than the CFU recovered from corneas treated with gatifloxacin (5.652 ± 0.396), and moxifloxacin (6.243 ± 0.387; P < 0.001). The average log10 CFU recovered from the PBS-treated corneas at 19 hours post-infection was 7.392 ± 0.095. All three of the fluoroquinolone treatments decreased the clinical severity compared to the control group (P < 0.010; n = 16 corneas per group). The clinical scores from the three treatment groups were not significantly different from each other (P > 0.050). The MICs for gatifloxacin and moxifloxacin against the MRSA strain were each 8 µg/ml, and the MIC for besifloxacin was 1 µg/ml.

Conclusions: : These data suggest that besifloxacin is more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the cornea when applied topically from 10 to 18 hours post-infection.

Keywords: antibiotics/antifungals/antiparasitics • keratitis • Staphylococcus 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×